USCOM LIMITED — Regulatory Filings 2017

Oct 15, 2017

ASX MEDIA RELEASE

BP+ and Mount Everest Hypertension Study New hypertension study demonstrates BP+ measures more sensitive than conventional arm BP measures

SYDNEY, Australia, Monday 16[th] October 2017: Uscom Limited (ASX code: UCM) (the Company or Uscom ) announced the publication of a study of 90 British servicemen and women and the effects on their central blood pressure (cBP) using the Uscom BP+ as they ascended from near sea level to a maximum of 5,360m over a period of 14 days in the Dhaulagiri region in the Himalayas at the base of Mount Everest. The study, published in the Journal of Human Hypertension and authored by experts from seven UK centres, found that systolic cBP measured by the Uscom BP+ was more sensitive than conventional systolic brachial (arm) BP for detecting the progressive BP changes of high altitude.

This study demonstrated that cBP was significantly different than brachial (arm) BP, and that BP+ determined systolic cBP increased proportionately more and changed earlier with the staged increase of cardiovascular work at incrementally increasing altitudes up to 5,360m. The pulse pressure wave parameter of augmentation index (AI) was not found to be independently associated with increasing altitude.

The researchers reported that “the accurate noninvasive assessment of cBP and large artery stiffness has been traditionally very difficult. It had required the need for either arterial catheterisation or less portable and expensive noninvasive equipment limiting its research utility at high altitude.” They also reported “(the Uscom BP+) has the advantage over several competing devices. It is highly portable and only requires the use of an upper arm cuff, and therefore avoiding the need to assess either the radial or digital pulse where the signal-to-noise ratio may be less favourable.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “This study demonstrates that Uscom BP+ measures more sensitively detect changes in BP than simple cuff BP measures. The study further establishes BP+ as the tool of choice for researchers and pharma as they evaluate new hypertension medications. It is also further proof of the applicability of the device in clinics and home care where the highest sensitivity of BP measurements are essential for appropriate management of hypertension. At Uscom we specialise in the development, manufacture and marketing of global practice leading technologies and believe that high accuracy measurements leads to improved clinical care. For Uscom this study comes as we prepare the new Uscom BP+ device for market release.”

Significance: Increased cardiac work is a feature of hypertension and a predictor of cardiac morbidity, mortality, and healthcare cost, and cBP is the new standard for measurement of BP and hypertension. At increasing altitude the air oxygen content is reduced and the heart has to work harder to deliver adequate oxygen to the cells. This study of the normal circulation as it incrementally adapts to increasing altitude, and increasing work, is a model that improves our understanding of the evolution of hypertension and the adaptation of the heart to the controlled incremental increase in work. For Uscom this is important research using the new BP+ device as the standard of BP measurement as it is finalised for release to market.

• Nearly 40% of all adults over the age of 25 years have diagnosed hypertension

• Hypertension is a factor in approximately 50% of all cardiac deaths and strokes

• Hypertension costs approximately $45B USD pa in the USA alone

• Improved measurement of BP may lead to improved therapy and reduced cost of hypertension management

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

Reference : 1.Boos CJ, Vincent E, Mellor A, Woods DR, New C, Cruttenden R, Barlow M, Cooke M, Deighton K, Scott P, Clarke S, O’Hara J. The effect of high altitude on central blood pressure and arterial stiffness. Journal of Human Hypertension 2017;31:715 – 719. 2.McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J

2014;doi10.1093/eurojeartj/eht565. 3. Roman M, Devereaux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central Pressure More Strongly Relates to Vascular Disease and Outcomes Than Does Brachial Pressure. The Strong Heart Study. Hypertension 2007;50:197-203. https://www.cdc.gov/bloodpressure/facts.htm

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specializing in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced hemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced hemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Pediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and pediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterization. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand-alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyze pulse pressure waves and generate a summary report.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialized for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand-alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyze spirometry outputs and generate a summary report.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au